New Advances in the Treatment of Acute Pancreatitis

  • Mahya Faghih
  • Christopher Fan
  • Vikesh K. SinghEmail author
Pancreas (V Chandrasekhara, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pancreas


Purpose of review

Despite the increasing incidence of acute pancreatitis, the overall mortality of AP has decreased.

Recent findings

The findings of recent studies on fluid therapy, analgesics, antibiotics, and enteral nutrition as well as the management of AP complications have led to improvements in clinical care. However, there are still no pharmacologic treatment(s) for AP.


Experimental studies have revealed many potential therapeutic targets, but these will need to be further developed and tested before they can be assessed in randomized controlled trials with important clinical endpoints.


Acute pancreatitis Treatment New advances Therapy 


Compliance with ethical standards

Conflict of interest

Mahya Faghih declares that she has no conflict of interest. Christopher Fan declares that he has no conflict of interest. Vikesh Singh reports personal fees from AbbVie, Akcea Therapeutics, Ariel Precision Medicine, and Orgenesis.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149:1741.e3.Google Scholar
  2. 2.
    Fagenholz PJ, Fernandez-del Castillo C, Harris NS, Pelletier AJ, Camargo CA. Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas. 2007a;35:302–7.CrossRefPubMedGoogle Scholar
  3. 3.
    • Krishna SG, Kamboj AK, Hart PA, Hinton A, Conwell DL. The changing epidemiology of acute pancreatitis hospitalizations: a decade of trends and the impact of chronic pancreatitis. Pancreas. 2017;46:482–8. Large administrative database study which showed that AP hospitalizations have increased but the overall mortality of AP has decreased over a 10-year period in the USA.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Fagenholz PJ, Castillo CF, Harris NS, Pelletier AJ, Camargo CA. Increasing United States hospital admissions for acute pancreatitis, 1988-2003. Ann Epidemiol. 2007b;17:491–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Acute pancreatitis classification working group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–11.CrossRefPubMedGoogle Scholar
  6. 6.
    Gorelick FS, Lerch MM. Do animal models of acute pancreatitis reproduce human disease? Cell Mol Gastroenterol Hepatol. 2017;4:251–62.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Afghani E, Pandol SJ, Shimosegawa T, Sutton R, Wu BU, Vege SS, et al. Acute pancreatitis-progress and challenges: a report on an international symposium. Pancreas. 2015;44:1195–210.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR, et al. Pharmacological interventions for acute pancreatitis. Cochrane Database Syst Rev. 2017;4:CD011384.PubMedGoogle Scholar
  9. 9.
    Singh VK, Moran RA, Afghani E, de-Madaria E. Treating acute pancreatitis: what’s new? Expert Rev Gastroenterol Hepatol. 2015;9:901–11.CrossRefPubMedGoogle Scholar
  10. 10.
    • Mounzer R, Langmead CJ, Wu BU, Evans AC, Bishehsari F, Muddana V, et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. Gastroenterology. 2012;142:6. First study, utilizing prospectively collected data, showing that the positive predictive value of current clinical scoring systems to predict persistent organ failure (severe acute pancreatitis) is low.CrossRefGoogle Scholar
  11. 11.
    Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48:62–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhao G, Zhang JG, Wu HS, Tao J, Qin Q, Deng SC, et al. Effects of different resuscitation fluid on severe acute pancreatitis. World J Gastroenterol. 2013;19:2044–52.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Vege SS, Atwal T, Bi Y, Chari ST, Clemens MA, Enders FT. Pentoxifylline treatment in severe acute pancreatitis: a pilot, double-blind, placebo-controlled, randomized trial. Gastroenterology. 2015;149:20.e3.CrossRefGoogle Scholar
  14. 14.
    • Buxbaum JL, Quezada M, Da B, Jani N, Lane C, Mwengela D, et al. Early aggressive hydration hastens clinical improvement in mild acute pancreatitis. Am J Gastroenterol. 2017;112:797–803 First RCT showing that aggressive hydration with lactated Ringer’s reduces the time to clinical improvement in patients with mild AP compared to standard hydration regimen.CrossRefPubMedGoogle Scholar
  15. 15.
    Vege SS, DiMagno MJ, Forsmark CE, Martel M, Barkun AN. Initial medical treatment of acute pancreatitis: American Gastroenterological Association Institute Technical Review. Gastroenterology. 2018;154:1103–39.Google Scholar
  16. 16.
    Haydock MD, Mittal A, van den Heever M, Rossaak JI, Connor S, Rodgers M, et al. Pancreas network of New Zealand. National survey of fluid therapy in acute pancreatitis: current practice lacks a sound evidence base. World J Surg. 2013;37:2428–35.CrossRefPubMedGoogle Scholar
  17. 17.
    de-Madaria E, Martinez J, Perez-Mateo M. The dynamic nature of fluid resuscitation in acute pancreatitis. Clin Gastroenterol Hepatol. 2012;10:6 author reply 96.Google Scholar
  18. 18.
    de-Madaria E, Banks PA, Moya-Hoyo N, Wu BU, Rey-Riveiro M, Acevedo-Piedra NG, et al. Early factors associated with fluid sequestration and outcomes of patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2014;12:997–1002.CrossRefPubMedGoogle Scholar
  19. 19.
    Wu BU, Hwang JQ, Gardner TH, Repas K, Delee R, Yu S, et al. Lactated Ringer’s solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011;9:717.e1.CrossRefGoogle Scholar
  20. 20.
    de-Madaria E, Herrera-Marante I, Gonzalez-Camacho V, Bonjoch L, Quesada-Vazquez N, Almenta-Saavedra I, et al. Fluid resuscitation with lactated Ringer's solution vs normal saline in acute pancreatitis: a triple-blind, randomized, controlled trial. United European Gastroenterol J. 2018;6:63–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Bhoomagoud M, Jung T, Atladottir J, Kolodecik TR, Shugrue C, Chaudhuri A, et al. Reducing extracellular pH sensitizes the acinar cell to secretagogue-induced pancreatitis responses in rats. Gastroenterology. 2009;137:1083–92.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Noble MD, Romac J, Vigna SR, Liddle RA. A pH-sensitive, neurogenic pathway mediates disease severity in a model of post-ERCP pancreatitis. Gut. 2008;57:1566–71.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559–63.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Iraporda C, Errea A, Romanin DE, Cayet D, Pereyra E, Pignataro O, et al. Lactate and short chain fatty acids produced by microbial fermentation downregulate proinflammatory responses in intestinal epithelial cells and myeloid cells. Immunobiology. 2015;220:1161–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Singh VK, Gardner TB, Papachristou GI, Rey-Riveiro M, Faghih M, Koutroumpakis E, et al. An international multicenter study of early intravenous fluid administration and outcome in acute pancreatitis. United European Gastroenterol J. 2017;5:491–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012;367:124–34.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Wiedermann CJ, Eisendle K. Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency. J Pharm Policy Pract. 2017;10:6. eCollection 2017.Google Scholar
  28. 28.
    Opperer M, Poeran J, Rasul R, Mazumdar M, Memtsoudis SG. Use of perioperative hydroxyethyl starch 6% and albumin 5% in elective joint arthroplasty and association with adverse outcomes: a retrospective population based analysis. BMJ. 2015;350:h1567.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wiedermann CJ. Hydroxyethyl starch--can the safety problems be ignored? Wien Klin Wochenschr. 2004;116:583–94.CrossRefPubMedGoogle Scholar
  30. 30.
    Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13:1.Google Scholar
  31. 31.
    Jin T, Jiang K, Deng L, Guo J, Wu Y, Wang Z, Shi N, Zhang X, Lin Z, Asrani V, Jones P, Mittal A, Phillips A, Sutton R, Huang W, Yang X, Xia Q, Windsor JA. Response and outcome from fluid resuscitation in acute pancreatitis: a prospective cohort study. HPB (Oxford). 2018.Google Scholar
  32. 32.
    Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN. American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology. 2018;154:1096–101.CrossRefPubMedGoogle Scholar
  33. 33.
    Capurso G, Zerboni G, Signoretti M, Valente R, Stigliano S, Piciucchi M, et al. Role of the gut barrier in acute pancreatitis. J Clin Gastroenterol. 2012;46(Suppl):46.CrossRefGoogle Scholar
  34. 34.
    • Bakker OJ, van Brunschot S, van Santvoort HC, Besselink MG, Bollen TL, Boermeester MA, et al. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. N Engl J Med. 2014;371:1983–93 This is the first study to show that similar outcomes can be achieved in patients randomized to an oral diet versus enteral feeds through nasojejunal tube in patients with predicted severe acute pancreatitis.CrossRefPubMedGoogle Scholar
  35. 35.
    Vaughn VM, Shuster D, Rogers MAM, Mann J, Conte ML, Saint S, et al. Early versus delayed feeding in patients with acute pancreatitis: a systematic review. Ann Intern Med. 2017;166:883–92.CrossRefPubMedGoogle Scholar
  36. 36.
    Whitlock TL, Repas K, Tignor A, Conwell D, Singh V, Banks PA, et al. Early readmission in acute pancreatitis: incidence and risk factors. Am J Gastroenterol. 2010;105:2492–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Li W, Liu J, Zhao S, Li J. Safety and efficacy of total parenteral nutrition versus total enteral nutrition for patients with severe acute pancreatitis: a meta-analysis. J Int Med Res. 2018;46:3948–58.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Song J, Zhong Y, Lu X, Kang X, Wang Y, Guo W, et al. Enteral nutrition provided within 48 hours after admission in severe acute pancreatitis: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e11871.CrossRefGoogle Scholar
  39. 39.
    Zhu Y, Yin H, Zhang R, Ye X, Wei J. Nasogastric nutrition versus nasojejunal nutrition in patients with severe acute pancreatitis: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2016;2016:6430632.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Basurto Ona X, Rigau Comas D, Urrutia G. Opioids for acute pancreatitis pain. Cochrane Database Syst Rev. 2013;(7):CD009179. doi:CD009179.Google Scholar
  41. 41.
    Gulen B, Dur A, Serinken M, Karcioglu O, Sonmez E. Pain treatment in patients with acute pancreatitis: a randomized controlled trial. Turk J Gastroenterol. 2016;27:192–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Meng W, Yuan J, Zhang C, Bai Z, Zhou W, Yan J, et al. Parenteral analgesics for pain relief in acute pancreatitis: a systematic review. Pancreatology. 2013;13:201–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Barlass U, Dutta R, Cheema H, George J, Sareen A, Dixit A, et al. Morphine worsens the severity and prevents pancreatic regeneration in mouse models of acute pancreatitis. Gut. 2018;67:600–2.PubMedGoogle Scholar
  44. 44.
    Sadowski SM, Andres A, Morel P, Schiffer E, Frossard JL, Platon A, et al. Epidural anesthesia improves pancreatic perfusion and decreases the severity of acute pancreatitis. World J Gastroenterol. 2015;21:12448–56.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Bulyez S, Pereira B, Caumon E, Imhoff E, Roszyk L, Bernard L, et al. AzuRea network Epidural analgesia in critically ill patients with acute pancreatitis: the multicentre randomised controlled EPIPAN study protocol. BMJ Open. 2017;7:015280.CrossRefGoogle Scholar
  46. 46.
    Cui ML, Kim KH, Kim HG, Han J, Kim H, Cho KB, et al. Incidence, risk factors and clinical course of pancreatic fluid collections in acute pancreatitis. Dig Dis Sci. 2014;59:1055–62.CrossRefPubMedGoogle Scholar
  47. 47.
    Varadarajulu S, Bang JY, Sutton BS, Trevino JM, Christein JD, Wilcox CM. Equal efficacy of endoscopic and surgical cystogastrostomy for pancreatic pseudocyst drainage in a randomized trial. Gastroenterology. 2013;145:90.e1.CrossRefGoogle Scholar
  48. 48.
    Alali A, Mosko J, May G, Teshima C. Endoscopic ultrasound-guided management of pancreatic fluid collections: update and review of the literature. Clin Endosc. 2017;50:117–25.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Besselink MG, Verwer TJ, Schoenmaeckers EJ, Buskens E, Ridwan BU, Visser MR, et al. Timing of surgical intervention in necrotizing pancreatitis. Arch Surg. 2007;142:1194–201.CrossRefPubMedGoogle Scholar
  50. 50.
    Connor S, Ghaneh P, Raraty M, Sutton R, Rosso E, Garvey CJ, et al. Minimally invasive retroperitoneal pancreatic necrosectomy. Dig Surg. 2003;20:270–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Bakker OJ, van Santvoort HC, van Brunschot S, Geskus RB, Besselink MG, Bollen TL, et al. Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial. JAMA. 2012;307:1053–61.CrossRefPubMedGoogle Scholar
  52. 52.
    • van Brunschot S, van Grinsven J, van Santvoort HC, Bakker OJ, Besselink MG, Boermeester MA, et al. Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial. Lancet. 2018;391:51–8. This RCT compared the endoscopic and surgical step-up approaches to symptomatic walled-off necrosis and showed that surgery was not superior to endoscopy with regard to both clinical and economic outcomes.CrossRefPubMedGoogle Scholar
  53. 53.
    Chandrasekaran P, Gupta R, Shenvi S, Kang M, Rana SS, Singh R, et al. Prospective comparison of long term outcomes in patients with severe acute pancreatitis managed by operative and non operative measures. Pancreatology. 2015;15:478–84.CrossRefPubMedGoogle Scholar
  54. 54.
    Sharaiha RZ, Tyberg A, Khashab MA, Kumta NA, Karia K, Nieto J, et al. Endoscopic therapy with lumen-apposing metal stents is safe and effective for patients with pancreatic walled-off necrosis. Clin Gastroenterol Hepatol. 2016;14:1797–803.CrossRefPubMedGoogle Scholar
  55. 55.
    Siddiqui AA, Adler DG, Nieto J, Shah JN, Binmoeller KF, Kane S, et al. EUS-guided drainage of peripancreatic fluid collections and necrosis by using a novel lumen-apposing stent: a large retrospective, multicenter U.S. experience (with videos). Gastrointest Endosc. 2016;83:699–707.CrossRefPubMedGoogle Scholar
  56. 56.
    Bapaye A, Itoi T, Kongkam P, Dubale N, Mukai S. New fully covered large-bore wide-flare removable metal stent for drainage of pancreatic fluid collections: results of a multicenter study. Dig Endosc. 2015;27:499–504.CrossRefPubMedGoogle Scholar
  57. 57.
    Rinninella E, Kunda R, Dollhopf M, Sanchez-Yague A, Will U, Tarantino I, et al. EUS-guided drainage of pancreatic fluid collections using a novel lumen-apposing metal stent on an electrocautery-enhanced delivery system: a large retrospective study (with video). Gastrointest Endosc. 2015;82:1039–46.CrossRefPubMedGoogle Scholar
  58. 58.
    Chandran S, Efthymiou M, Kaffes A, Chen JW, Kwan V, Murray M, et al. Management of pancreatic collections with a novel endoscopically placed fully covered self-expandable metal stent: a national experience (with videos). Gastrointest Endosc. 2015;81:127–35.CrossRefPubMedGoogle Scholar
  59. 59.
    Dhir V, Teoh AY, Bapat M, Bhandari S, Joshi N, Maydeo A. EUS-guided pseudocyst drainage: prospective evaluation of early removal of fully covered self-expandable metal stents with pancreatic ductal stenting in selected patients. Gastrointest Endosc. 2015;82:5.Google Scholar
  60. 60.
    Shah RJ, Shah JN, Waxman I, Kowalski TE, Sanchez-Yague A, Nieto J, et al. Safety and efficacy of endoscopic ultrasound-guided drainage of pancreatic fluid collections with lumen-apposing covered self-expanding metal stents. Clin Gastroenterol Hepatol. 2015;13:747–52.CrossRefPubMedGoogle Scholar
  61. 61.
    Walter D, Will U, Sanchez-Yague A, Brenke D, Hampe J, Wollny H, et al. A novel lumen-apposing metal stent for endoscopic ultrasound-guided drainage of pancreatic fluid collections: a prospective cohort study. Endoscopy. 2015;47:63–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Vazquez-Sequeiros E, Baron TH, Perez-Miranda M, Sanchez-Yague A, Gornals J, Gonzalez-Huix F, et al. Evaluation of the short- and long-term effectiveness and safety of fully covered self-expandable metal stents for drainage of pancreatic fluid collections: results of a Spanish nationwide registry. Gastrointest Endosc. 2016;84:457.e2.CrossRefGoogle Scholar
  63. 63.
    Nabi Z, Basha J, Reddy DN. Endoscopic management of pancreatic fluid collections-revisited. World J Gastroenterol. 2017;23:2660–72.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    • Bang JY, Navaneethan U, Hasan MK, Sutton B, Hawes R, Varadarajulu S. Non-superiority of lumen-apposing metal stents over plastic stents for drainage of walled-off necrosis in a randomised trial. Gut. 2018. This RCT compared plastic and metal stents for the drainage of symptomatic walled-off necrosis and showed that there was no significant difference in treatment outcomes.Google Scholar
  65. 65.
    Werge M, Novovic S, Schmidt PN, Gluud LL. Infection increases mortality in necrotizing pancreatitis: a systematic review and meta-analysis. Pancreatology. 2016;16:698–707.CrossRefPubMedGoogle Scholar
  66. 66.
    Mourad MM, Evans R, Kalidindi V, Navaratnam R, Dvorkin L, Bramhall SR. Prophylactic antibiotics in acute pancreatitis: endless debate. Ann R Coll Surg Engl. 2017;99:107–12.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Lee HS, Lee SK, Park DH, Lee SS, Seo DW, Kim MH, et al. Emergence of multidrug resistant infection in patients with severe acute pancreatitis. Pancreatology. 2014;14:450–3.CrossRefPubMedGoogle Scholar
  68. 68.
    Brown LA, Hore TA, Phillips AR, Windsor JA, Petrov MS. A systematic review of the extra-pancreatic infectious complications in acute pancreatitis. Pancreatology. 2014;14:436–43.CrossRefPubMedGoogle Scholar
  69. 69.
    • Guo Q, Li A, Xia Q, Liu X, Tian B, Mai G, et al. The role of organ failure and infection in necrotizing pancreatitis: a prospective study. Ann Surg. 2014;259:1201–7. One of the first large studies to show that organ failure is a stronger determinant of mortality in patients with necrotizing pancreatitis as compared with local infection.CrossRefPubMedGoogle Scholar
  70. 70.
    Besselink MG, van Santvoort HC, Boermeester MA, Nieuwenhuijs VB, van Goor H, Dejong CH, et al. Timing and impact of infections in acute pancreatitis. Br J Surg. 2009;96:267–73.CrossRefPubMedGoogle Scholar
  71. 71.
    Mouli VP, Sreenivas V, Garg PK. Efficacy of conservative treatment, without necrosectomy, for infected pancreatic necrosis: a systematic review and meta-analysis. Gastroenterology. 2013;144:340.e2.CrossRefGoogle Scholar
  72. 72.
    • Kochar B, Akshintala VS, Afghani E, Elmunzer BJ, Kim KJ, Lennon AM, et al. Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. Gastrointest Endosc. 2015;81:149.e9. This systematic review of the placebo and no-stent arms of 108 RCTs provides accurate incidence estimates of PEP, severe PEP, and PEP-associated mortality which can be used for sample size calculations for future RCT as well as patient informed consent for ERCP procedures.CrossRefGoogle Scholar
  73. 73.
    Andrade-Davila VF, Chavez-Tostado M, Davalos-Cobian C, Garcia-Correa J, Montano-Loza A, Fuentes-Orozco C, et al. Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial. BMC Gastroenterol. 2015;15:2.CrossRefGoogle Scholar
  74. 74.
    Luo H, Zhao L, Leung J, Zhang R, Liu Z, Wang X, et al. Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, single-blinded, randomised controlled trial. Lancet. 2016;387:2293–301.CrossRefPubMedGoogle Scholar
  75. 75.
    Thiruvengadam NR, Forde KA, Ma GK, Ahmad N, Chandrasekhara V, Ginsberg GG, et al. Rectal indomethacin reduces pancreatitis in high- and low-risk patients undergoing endoscopic retrograde cholangiopancreatography. Gastroenterology. 2016;151:297.e4.CrossRefGoogle Scholar
  76. 76.
    Del Olmo ML, Velayos Jimenez B, Almaraz GA. Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients. Rev Esp Enferm Dig. 2018;110.
  77. 77.
    Okuno M, Shiroko J, Taguchi D, Yamaguchi K, Takada J, Imai S, Sato H, Thanabashi S. The effectiveness of the rectal administration of low-dose diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Intern Med. 2018.Google Scholar
  78. 78.
    de Quadros OF, Lima JCP, Watte G, Lehmen RL, Oba D, Camargo G, et al. C E O Prophylaxis of pancreatitis with intravenous ketoprofen in a consecutive population of ERCP patients: a randomized double-blind placebo-controlled trial. Surg Endosc. 2017;31:2317–24.CrossRefGoogle Scholar
  79. 79.
    • Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012;366:1414–22. First adequately powered RCT to show the efficacy of rectal indomethacin for the prevention of post-ERCP pancreatitis in high-risk patients compared to placebo.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Kato K, Shiba M, Kakiya Y, Maruyama H, Ominami M, Fukunaga S, et al. Celecoxib oral administration for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized prospective trial. Pancreas. 2017;46:880–6.CrossRefPubMedGoogle Scholar
  81. 81.
    Park SW, Chung MJ, Oh TG, Park JY, Bang S, Park SW, et al. Intramuscular diclofenac for the prevention of post-ERCP pancreatitis: a randomized trial. Endoscopy. 2015;47:33–9.PubMedGoogle Scholar
  82. 82.
    Choksi NS, Fogel EL, Cote GA, Romagnuolo J, Elta GH, Scheiman JM, et al. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement. Gastrointest Endosc. 2015;81:150–5.CrossRefPubMedGoogle Scholar
  83. 83.
    •• Elmunzer BJ, Serrano J, Chak A, Edmundowicz SA, Papachristou GI, Scheiman JM, et al. Rectal indomethacin alone versus indomethacin and prophylactic pancreatic stent placement for preventing pancreatitis after ERCP: study protocol for a randomized controlled trial. Trials. 2016;17:2. Ongoing RCT, currently in its 4th year (planned 5-year trial), testing the hypothesis that rectal indomethacin is noninferior to the combination of rectal indomethacin and pancreatic stent placement for the prevention of post-ERCP pancreatitis in high-risk patients.CrossRefGoogle Scholar
  84. 84.
    • Choi JH, Kim HJ, Lee BU, Kim TH, Song IH. Vigorous Periprocedural hydration with lactated Ringer’s solution reduces the risk of pancreatitis after retrograde cholangiopancreatography in hospitalized patients. Clin Gastroenterol Hepatol. 2017;15:92.e1. First RCT to show that periprocedural fluid therapy with lactated Ringer’s reduces the incidence and severity of post-ERCP pancreatitis in average-risk patients.Google Scholar
  85. 85.
    Mok SRS, Ho HC, Shah P, Patel M, Gaughan JP, Elfant AB. Lactated Ringer’s solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial. Gastrointest Endosc. 2017;85:1005–13.CrossRefPubMedGoogle Scholar
  86. 86.
    Smeets XJNM, da Costa DW, Fockens P, Mulder CJJ, Timmer R, Kievit W, et al. Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial. Trials. 2018;19:x.CrossRefGoogle Scholar
  87. 87.
    de Pretis N, Amodio A, Frulloni L. Hypertriglyceridemic pancreatitis: epidemiology, pathophysiology and clinical management. United European Gastroenterol J. 2018;6:649–55.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48:195–203.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    • Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176:1834–42. Large population-based study from Scandanavia that showed an increased risk of AP in patients with lower triglyceride levels than prior studies.CrossRefPubMedGoogle Scholar
  90. 90.
    Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol. 2011;107:891–7.CrossRefPubMedGoogle Scholar
  91. 91.
    Nawaz H, Koutroumpakis E, Easler J, Slivka A, Whitcomb DC, Singh VP, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110:1497–503.CrossRefPubMedGoogle Scholar
  92. 92.
    Christian JB, Arondekar B, Buysman EK, Jacobson TA, Snipes RG, Horwitz RI. Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia. Am J Med. 2014;127:44.e1.CrossRefGoogle Scholar
  93. 93.
    Ahmad Z, Halter R, Stevenson M. Building a better understanding of the burden of disease in familial chylomicronemia syndrome. Expert Rev Clin Pharmacol. 2017;10:1–3.CrossRefPubMedGoogle Scholar
  94. 94.
    Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11:352–62.CrossRefPubMedGoogle Scholar
  95. 95.
    Stroes E, Moulin P, Parhofer KG, Rebours V, Lohr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl. 2017;23:1–7.CrossRefPubMedGoogle Scholar
  96. 96.
    Hwang SS, Li BH, Haigh PI. Gallstone pancreatitis without cholecystectomy. JAMA Surg. 2013;148:867–72.CrossRefPubMedGoogle Scholar
  97. 97.
    Yadav D, O'Connell M, Papachristou GI. Natural history following the first attack of acute pancreatitis. Am J Gastroenterol. 2012;107:1096–103.CrossRefPubMedGoogle Scholar
  98. 98.
    da Costa DW, Dijksman LM, Bouwense SA, Schepers NJ, Besselink MG, van Santvoort HC, et al. Dutch Pancreatitis Study Group. Cost-effectiveness of same-admission versus interval cholecystectomy after mild gallstone pancreatitis in the PONCHO trial. Br J Surg. 2016;103:1695–703.CrossRefPubMedGoogle Scholar
  99. 99.
    • Schepers NJ, on behalf of the Dutch Pancreatitis Study Group. Early endoscopic retrograde cholangiography with biliary sphincterotomy or conservative treatment in predicted severe acute biliary pancreatitis (Apec): a multicenter randomized controlled trial, In: UEG week 2018; October 20-24; Austria. United European Gastroenterol J. 2018;6(8S):A1–A134 The preliminary data from this RCT shows that, in patients with predicted severe acute biliary pancreatitis without cholangitis, early ERC within 24 h of presentation to the emergency department did not reduce mortality.Google Scholar
  100. 100.
    Ahmed Ali U, Issa Y, Hagenaars JC, Bakker OJ, van Goor H, Nieuwenhuijs VB, et al. Dutch Pancreatitis Study Group. Risk of recurrent pancreatitis and progression to chronic pancreatitis after a first episode of acute pancreatitis. Clin Gastroenterol Hepatol. 2016;14:738–46.CrossRefPubMedGoogle Scholar
  101. 101.
    Nordback I, Pelli H, Lappalainen-Lehto R, Jarvinen S, Raty S, Sand J. The recurrence of acute alcohol-associated pancreatitis can be reduced: a randomized controlled trial. Gastroenterology. 2009;136:848–55.CrossRefPubMedGoogle Scholar
  102. 102.
    Han S, Kheder J, Bocelli L, Fahed J, Wachholtz A, Seward G, et al. Smoking cessation in a chronic pancreatitis population. Pancreas. 2016;45:1303–8.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
  104. 104.
    • Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology. 2011;140:153–61 This is the first study showing the risk of pancreatitis across different CFTR genotypes in patients with cystic fibrosis.CrossRefPubMedGoogle Scholar
  105. 105.
    LaRusch J, Jung J, General IJ, Lewis MD, Park HW, Brand RE, et al. Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genet. 2014;10:e1004376.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Carrion A, Borowitz DS, Freedman SD, Siracusa CM, Goralski JL, Hadjiliadis D, et al. Reduction of recurrence risk of pancreatitis in cystic fibrosis with ivacaftor: case series. J Pediatr Gastroenterol Nutr. 2018;66:451–4.CrossRefPubMedGoogle Scholar
  107. 107.
    Lagoo JY, D'Souza MC, Kartha A, Kutappa AM. Role of ulinastatin, a trypsin inhibitor, in severe acute pancreatitis in critical care setting: a retrospective analysis. J Crit Care. 2018;45:27–32.CrossRefPubMedGoogle Scholar
  108. 108.
    Wang LZ, Luo MY, Zhang JS, Ge FG, Chen JL, Zheng CQ. Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment: a meta-analysis. Int J Clin Pharmacol Ther. 2016;54:890–8.CrossRefPubMedGoogle Scholar
  109. 109.
    Xu B, Bai B, Sha S, Yu P, An Y, Wang S, et al. Interleukin-1beta induces autophagy by affecting calcium homeostasis and trypsinogen activation in pancreatic acinar cells. Int J Clin Exp Pathol. 2014;7:3620–31.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Chao KC, Chao KF, Chuang CC, Liu SH. Blockade of interleukin 6 accelerates acinar cell apoptosis and attenuates experimental acute pancreatitis in vivo. Br J Surg. 2006;93:332–8.CrossRefPubMedGoogle Scholar
  111. 111.
    Mazzon E, Impellizzeri D, Di Paola R, Paterniti I, Esposito E, Cappellani A, et al. Effects of mitogen-activated protein kinase signaling pathway inhibition on the development of cerulein-induced acute pancreatitis in mice. Pancreas. 2012;41:560–70.CrossRefPubMedGoogle Scholar
  112. 112.
    Xu P, Wang J, Yang ZW, Lou XL, Chen C. Regulatory roles of the PI3K/Akt signaling pathway in rats with severe acute pancreatitis. PLoS One. 2013;8:e81767.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mahya Faghih
    • 1
  • Christopher Fan
    • 2
  • Vikesh K. Singh
    • 1
    • 3
    Email author
  1. 1.Division of GastroenterologyJohns Hopkins Medical InstitutionsBaltimoreUSA
  2. 2.Department of MedicineJohns Hopkins Medical InstitutionsBaltimoreUSA
  3. 3.Pancreatitis CenterJohns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations